Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials (Q40068353)

17 September 2017

Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials (English)

1 reference

17 September 2017

phase I clinical trial

0 references

19

Susanna Brighenti

0 references

Maria Norrby

Maria Norrby

1

0 references

Peter Andersen

Peter Andersen

14

0 references

Markus Maeurer

Markus Maeurer

4

0 references

Sean Bennett

Sean Bennett

7

0 references

Tom H M Ottenhoff

17

Tom H M Ottenhoff

1 reference

17 September 2017

16

Simone A Joosten

1 reference

17 September 2017

Timo Vesikari

2

1 reference

17 September 2017

Lars Lindqvist

3

1 reference

17 September 2017

Raija Ahmed

5

1 reference

17 September 2017

Shahnaz Mahdavifar

6

1 reference

17 September 2017

J Bruce McClain

8

1 reference

17 September 2017

Barbara M Shepherd

9

1 reference

17 September 2017

Daner Li

10

1 reference

17 September 2017

David A Hokey

11

1 reference

17 September 2017

Ingrid Kromann

12

1 reference

17 September 2017

Søren T Hoff

13

1 reference

17 September 2017

Adriëtte W de Visser

15

1 reference

17 September 2017

Jan Andersson

18

1 reference

17 September 2017

language of work or name

English

0 references

publication date

16 February 2017

1 reference

17 September 2017

1 reference

17 September 2017

35

1 reference

17 September 2017

1652-1661

1 reference

17 September 2017

12

1 reference

BCG vaccine: efficacy and indications for vaccination and revaccination

17 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

A family of cross-reacting proteins secreted by Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

Early T-cell responses in tuberculosis immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

Detection of proliferative responses to ESAT-6 and CFP-10 by FASCIA assay for diagnosis of Mycobacterium tuberculosis infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

T-cell quality in memory and protection: implications for vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

Vaccines against tuberculosis: where are we and where do we need to go?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

Comparison of the predicted population coverage of tuberculosis vaccine candidates Ag85B-ESAT-6, Ag85B-TB10.4, and Mtb72f via a bioinformatics approach.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

Induction and regulation of CD8+ cytolytic T cells in human tuberculosis and HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

CD8alpha alpha memory effector T cells descend directly from clonally expanded CD8alpha +beta high TCRalpha beta T cells in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

The two-component adjuvant IC31® boosts type i interferon production of human monocyte-derived dendritic cells via ligation of endosomal TLRs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

Effects of KLK Peptide on Adjuvanticity of Different ODN Sequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

Prime-boost vaccination with rBCG/rAd35 enhances CD8⁺ cytolytic T-cell responses in lesions from Mycobacterium tuberculosis-infected primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

Deletion of nuoG from the Vaccine Candidate Mycobacterium bovis BCG ΔureC::hly Improves Protection against Tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.055

10.1016/J.VACCINE.2017.01.055

7 January 2021

Identifiers

DOI

1 reference

17 September 2017

1 reference